Peptides Vietnam LogoPeptides Vietnam
EN/VI
Molecule MechanicsNov 2026

CBL-514: What Is It and How the Fat Reduction Injection Works

CBL-514 is an experimental shot designed to make fat cells in one small spot shut themselves down, instead of bursting them. It comes from Caliway Biopharmaceuticals in Taiwan, and as of 15 November 2026 it is not approved in any country.

Three human trials have measured abdominal fat after CBL-514. The largest put 108 adults into two groups, and it found about 20% less abdominal fat on MRI on average. Much of how it works on the cell, though, rests on company work that is not fully published. Its first Phase 3 trial began in September 2026.

On this page

Key facts

What it is: An experimental small molecule, not a peptide or protein, given as a shot into fat under the skin.

The idea: Fat cells at the treated spot switch themselves off (apoptosis) instead of bursting, as the company describes its design.

Best human data: In a Phase 2b trial, 23 of 30 people analyzed improved on a clinician abdominal fat scale, against 7 of 37 on placebo.

The big gaps: The cell mechanism is unpublished company work, the analysis groups were small, and no published trial has established how long the fat reduction lasts.

Status on 15 November 2026: Investigational, approved nowhere, and no FDA application found. Phase 3 began in September 2026.

Sources: Caliway news release, 25 August 2026; Phase 2b paper, Aesthetic Surgery Journal, 2026; Phase 2a paper, Goodman and colleagues, 2022; Caliway website, read 15 November 2026

What is CBL-514?

CBL-514 is a drug in testing that aims to reduce fat under the skin in the one area where it is given. Caliway Biopharmaceuticals, based in New Taipei City, Taiwan, develops it. The company was founded in 2012 and trades on the Taiwan Stock Exchange.

It is a small molecule. That sets it apart from most drugs in this series, which are peptides, meaning chains of amino acids. Picture a peptide as a long necklace of beads and CBL-514 as one small charm on a key ring. Caliway calls it first-in-class, which is the company's own label for a drug that works in a new way.

Its first test in people was a Phase 1 safety study of 40 healthy volunteers in Australia, from November 2018 to August 2019. Most groups in that study were randomized and double-blind, but the last groups knew what they got. We found no published story of who first made the molecule, or how.

Sources: Phase 2 paper, 2025; Caliway news release, 25 August 2026; ClinicalTrials.gov NCT04699669

How does CBL-514 work on fat cells?

CBL-514 is designed to make fat cells at the treated spot die by apoptosis, or programmed cell death, as the company describes its design. Think of taking a building apart floor by floor rather than using a wrecking ball.

The company's account. Caliway's lab work says CBL-514 blocks DYRK1b, an enzyme that helps fat cells stay alive. An enzyme is a protein that does a job in the cell. With that helper blocked, the company reports, death signals called caspase 3 and the Bax to Bcl-2 ratio go up. A 2022 paper with Caliway staff among its authors states this, but it cites unpublished confidential company reports for it. So this part is a company claim, not settled science.

What was published. In cell studies, CBL-514 set off both fat breakdown, called lipolysis, and fat cell apoptosis. In animals, it caused fat cell apoptosis and shrank fat under the skin where it was given. These are cell and animal results, not results in people.

What is still unknown. The full chemical structure and the full mechanism have not been published. Company reports also say CBL-514 reduced fat in lab and animal work without skin death, ulcers, nerve injury or whole-body effects. Those reports are not public either.

Sources: Caliway news release, 25 August 2026; Phase 2a paper, Goodman and colleagues, 2022; Phase 2 paper, 2025

How is CBL-514 different from Kybella?

Kybella breaks fat cells open, while CBL-514 is designed to make them shut down quietly. Kybella is deoxycholic acid, a bile acid that the body makes to help break up fat in the gut. Its FDA label says it physically destroys the fat cell's outer wall, so the cell bursts.

Kybella got FDA approval on 29 April 2015. It is approved only for fullness from fat under the chin in adults, and not for fat anywhere else on the body. A 2025 systematic review says deoxycholic acid is still the only agent approved in the US for fat under the chin.

Why picky matters. The 2022 CBL-514 paper calls deoxycholic acid relatively nonselective. It mainly hits fat cells but can also harm muscle and nearby tissue. Many existing non-surgical fat reduction methods, and shots based on deoxycholic acid or phosphatidylcholine, work the same way: they damage fat cells so they die by necrosis, and immune cells then clear the spilled fat. Note that this framing comes from researchers who work with Caliway, a competitor.

Kybella's label warns about injury to a nerve near the jaw, trouble swallowing, hair loss at the site, and skin ulcers or tissue death. Its most common side effects, each in over 20% of people in trials, were swelling, bruising, pain, numbness, redness and hardening at the site. CBL-514 is designed to be pickier, but that claim rests on company lab and animal work.

Sources: Kybella label via openFDA; Drugs@FDA record, NDA 206333; Review of fat-reducing injectables (PMID 42488923); Systematic review, November 2025; Phase 2a paper, Goodman and colleagues, 2022

How is CBL-514 different from GLP-1 drugs?

The Wegovy label describes a different path from CBL-514, which is aimed at fat in one treated spot. According to that label, the semaglutide in Wegovy switches on the GLP-1 receptor, which helps regulate appetite and how much a person eats. That receptor is found in brain areas tied to appetite. The label describes appetite control, not a target in fat cells at one spot.

Three ways a drug can reduce fat, from each drug's label or company source, checked November 2026.
DrugWhat it isHow it actsWhereStatus
CBL-514Experimental small moleculeDesigned to make fat cells at the treated spot shut themselves down (apoptosis), per the companyFat under the skin where it is givenInvestigational, not approved in any country
Kybella (deoxycholic acid)A bile acid the body also makesBreaks the fat cell wall so the cell bursts, per its FDA labelFat under the chinApproved in the US in April 2015, adults only
Wegovy (semaglutide)Peptide copy of the gut hormone GLP-1Acts on GLP-1 receptors in brain areas tied to appetite, per its labelBody weight overall, not one spotApproved in the US for long-term weight management

For how two GLP-1 copies were built to last, see our Saxenda vs Wegovy article. Tirzepatide, which adds a second hormone lock, is drawn out in our animated tirzepatide explainer.

Sources: Wegovy label via openFDA; Kybella label via openFDA; Caliway news release, 25 August 2026; Caliway website, read 15 November 2026

What did the CBL-514 trials find?

All three published trials found less abdominal fat in the treated area, but each had real limits. Every number below measures fat where the drug was given. None of them measures body weight.

Published CBL-514 trials for abdominal fat, from the trial papers.
TrialPeopleWhat it measuredMain limit
Phase 2a (Australia, 2020)43 enrolled, no placebo groupAt the highest level tested, abdominal fat volume was down about 25% on average at the first follow-up, by ultrasound, in the per-protocol analysis (the 24 people who followed the plan)Open-label, one site, no placebo
Phase 2 (US and Australia, 2022 to 2023)76 randomized, 2 to 1 against placebo16 of 23 with results lost at least 150 mL of abdominal fat 8 weeks after the last treatment; 0 of 16 on placeboAbout half (49.3%) did not finish
Phase 2b (US, CBL-0204)108 adults randomized, half to placebo23 of 30 analyzed (76.7%) improved at least one grade on a clinician fat scale at 12 weeks, against 7 of 37 (18.9%); MRI showed about 20% less abdominal fatOnly 67 of 108 were in the analysis

The 2020 study. It ran at one site in Australia and planned 47 people. COVID-19 cut recruiting short at 43. There was no placebo, or dummy treatment, so nothing to compare against.

The 2022 to 2023 study. This one did have a placebo group. At the 4 week follow-up, the CBL-514 group had lost over 200 mL more fat on average than placebo, and the gap held to 8 weeks. But 49.3% of people did not finish. Most were lost to follow-up, withdrew or had weight changes. So the 8 week share rests on just 23 and 16 people.

The Phase 2b. The paper says 108 adults were randomized, and the trial registry lists 107. Yet only 67 of them were in the main analysis: 30 on CBL-514 and 37 on placebo. MRI showed an average drop of about 153 mL, or 20%. Patients rated their own results in a similar way, 23 of 30 against 7 of 36.

Unpublished trials. A second Phase 2b with 173 people finished in October 2024 and has no results on its registry page. No CBL-514 trial has results posted on ClinicalTrials.gov. Read them as averages across small groups. They cannot tell what would happen for one reader.

Sources: Phase 2a paper, Goodman and colleagues, 2022; Phase 2 paper, 2025; Phase 2b paper, Aesthetic Surgery Journal, 2026; ClinicalTrials.gov NCT06005441

Why is CBL-514 being tested with Zepbound?

CBL-514 is being paired with Zepbound because of one animal study on weight regain. Zepbound is tirzepatide. It got FDA approval in November 2023 for chronic weight management, in adults who have obesity, or overweight along with at least one health problem linked to weight.

The animal result. In June 2026, Caliway shared an animal study at the ADA meeting. After the drugs were stopped, weight came back by 46.1% with tirzepatide alone. With CBL-514 added, it came back by 17.1%. The news release does not name the animal, and the study has not been peer reviewed.

The trial. In August 2026, the FDA cleared Caliway's application to start a Phase 2 trial, CBL-0201WR, testing CBL-514 with Zepbound in people. Clearing a trial lets it begin. It is not an approval of either drug for this use.

Our guide on how long you can stay on Zepbound covers what the Zepbound research says, and our semaglutide vs tirzepatide article compares the two best-known weight drugs.

Sources: FDA news release on Zepbound, November 2023; Caliway news release on the animal study, 11 June 2026; Caliway news release, 25 August 2026

What are the side effects of CBL-514?

The side effects reported so far are mostly at the treated spot. Here is what each trial paper reported.

  • 2020 study: every person had at least one side effect. Most were at the treated spot: bruising, redness, pain, swelling, itching or hardening. About 80% of the events were mild and about 19% moderate, and most cleared within 2 weeks. Even so, 8 of 43 people left the study because of side effects. There were no serious events.
  • 2022 to 2023 study: nearly all treatment-related side effects were mild to moderate reactions at the spot that cleared before the study ended. One serious event, a cancer that had spread to the lining of the abdomen, was judged unrelated to treatment.
  • Blood fats: in that same study, two people who already had high cholesterol showed raised blood fats at one visit. In one of them, the doctors judged it probably related to treatment.
  • Phase 2b: the paper calls CBL-514 well tolerated, with mainly mild, short-lived reactions at the spot.

These trials were small and short, so they cannot establish whether rare or late side effects occur. Only a treating doctor can judge risks for one person.

Sources: Phase 2a paper, Goodman and colleagues, 2022; Phase 2 paper, 2025; Phase 2b paper, Aesthetic Surgery Journal, 2026

How strong is the evidence for each CBL-514 claim?

The claims about CBL-514 rest on very different kinds of proof. This table sorts each one by where it comes from and whether outside scientists can check it.

Each claim, the kind of study behind it, and whether the data are published, as of 15 November 2026.
ClaimKind of evidencePublished for others to check?
It blocks a fat cell survival enzyme called DYRK1bCompany lab and animal workNo. The paper cites unpublished confidential company reports
It triggers fat breakdown and fat cell apoptosisCell and animal studiesReported in a peer-reviewed paper with company authors
It caused no skin death, ulcers or nerve injury in lab workCompany nonclinical studiesNo. Cited to unpublished company reports
It reduces abdominal fat in peopleThree human trials, the largest with 108 peopleYes, in peer-reviewed papers, with small analysis groups
Adding it to tirzepatide cuts weight regainOne animal study, species not namedNo. Company news release only
The fat stays gone over yearsNone yetA long-term follow-up study is planned, not started

The same review that names deoxycholic acid as the lone chin fat agent also says more trials are needed on long-term results for fat shots used elsewhere on the body. That call covers the whole group, CBL-514 included.

Sources: Phase 2a paper, Goodman and colleagues, 2022; Phase 2 paper, 2025; Phase 2b paper, Aesthetic Surgery Journal, 2026; Caliway news release on the animal study, 11 June 2026; ClinicalTrials.gov NCT07733947; Systematic review, November 2025

What else is CBL-514 being studied for?

Besides abdominal fat, CBL-514 has been tested for cellulite and for Dercum disease. Two small open-label cellulite studies, of 12 and 23 people, have finished. No peer-reviewed results from them were found.

Dercum disease. This rare condition causes painful fatty lumps called lipomas. In an open-label study of 12 US adults, the median lipoma size fell by roughly 45% to 59%, across groups and visits. It had no placebo group. All 12 had a treatment-related side effect, 4 had a severe one, and 2 stopped treatment. There were no serious events.

A later placebo-controlled study of 19 people met its pain goal, Caliway says. The average pain score fell 3.1 points, against 1.9 on placebo, at week 20. That result is company-reported and not yet peer reviewed. The FDA gave CBL-514 Fast Track status for Dercum disease, which allows more frequent contact with the FDA during development. Separately, Caliway says it holds FDA orphan drug status and European orphan status for Dercum disease, a claim from its own news release. None of these is an approval.

Sources: ClinicalTrials.gov NCT05836779; Dercum disease Phase 2a paper; Caliway news release on Dercum disease, 22 September 2026; Review of fat-reducing injectables (PMID 42488923); Taiwan News report of a Caliway release, November 2024

Is CBL-514 approved?

No. As of 15 November 2026, Caliway says CBL-514 is investigational, has no marketing approval in any country and is not sold in any market. Our search of the FDA drug approval database that same day found no application from Caliway.

Phase 3. SUPREME-01 is the first Phase 3 trial. It is randomized and placebo-controlled, with about 320 people planned in the US and Canada. The registry lists its start as 1 September 2026. Its main goal is the share of people who improve by at least 2 grades on both a patient and a clinician abdominal fat scale. The registry estimates primary completion in July 2027.

More trials queued. A second Phase 3, SUPREME-02, plans about 320 people in the US, Canada and Australia. The registry listed it as not yet recruiting on 20 October 2026, though Caliway's site says enrollment has begun. A Phase 3b study is registered to follow people who finish either trial, to test whether results last and long-term safety. It was not yet recruiting in October 2026.

We re-read each status fact on this page against the company site, the trial registry and the FDA database on the day of writing, following our medical review policy.

Sources: Caliway website, read 15 November 2026; ClinicalTrials.gov NCT07140939 (SUPREME-01); ClinicalTrials.gov NCT07526974 (SUPREME-02); ClinicalTrials.gov NCT07733947; Caliway news release, 25 August 2026

What else do people ask about CBL-514?

What is CBL-514?+

CBL-514 is an experimental drug from Caliway Biopharmaceuticals, a company in New Taipei City, Taiwan. It is a small molecule, not a peptide or a protein. It is given as a shot under the skin and is designed to shrink fat in the treated area. As of 15 November 2026 it is not approved in any country.

How does CBL-514 work?+

Caliway says CBL-514 is designed to make fat cells at the treated spot die by apoptosis, or programmed cell death, rather than bursting. Company lab work says it blocks an enzyme called DYRK1b that helps fat cells survive. That part rests on company reports that are not fully published.

Is CBL-514 approved in the US?+

No. Caliway says CBL-514 has no marketing approval in any country and is not sold anywhere. A search of the FDA drug approval database on 15 November 2026 found no Caliway application. In August 2026 the FDA cleared a new trial of it, which lets the trial start but is not an approval.

Is CBL-514 the same as Kybella?+

No. Kybella is deoxycholic acid, and its FDA label says it breaks the fat cell wall so the cell bursts. It is approved in the US only for fat under the chin in adults. CBL-514 is a different molecule designed to make fat cells shut down more quietly, and it is still in trials for abdominal fat.

Is CBL-514 a GLP-1 drug?+

No. The Wegovy label says its semaglutide acts on the GLP-1 receptor, a regulator of appetite and food intake found in brain areas tied to appetite. CBL-514 is aimed at fat cells in the one spot where it is given. Its trials measured fat in the treated area, not body weight.

How much fat did CBL-514 remove in trials?+

In the Phase 2b trial, MRI showed abdominal fat down about 20% on average. On a clinician fat scale, 23 of 30 people analyzed improved, against 7 of 37 on placebo. An earlier Phase 2 found 16 of 23 with results lost at least 150 mL of fat, against none on placebo. These are group averages from small analysis groups.

What are the side effects of CBL-514?+

In the 2020 study, every person had at least one side effect, mostly bruising, redness, pain or swelling at the treated spot. Most were mild and cleared within about two weeks, but 8 of 43 left the study because of them. Later trials mostly saw mild to moderate, short-lived reactions at the spot.

Why is CBL-514 being tested with Zepbound?+

In an animal study shared by Caliway in June 2026, weight regain after stopping was 46.1% with tirzepatide alone and 17.1% when CBL-514 was added. That is animal data from a news release and has not been peer reviewed. In August 2026 the FDA cleared a Phase 2 trial to test the pair in people.

Does the fat stay gone after CBL-514?+

No published trial has shown how long the fat reduction lasts. The published trials followed people for weeks after treatment. A Phase 3b study is registered to follow people who finish the main Phase 3 trials for longer, but it was not yet recruiting in October 2026.

What is the CBL-514 Phase 3 trial?+

SUPREME-01 is the first Phase 3 trial. It is randomized and placebo-controlled, with about 320 people planned in the US and Canada. The registry lists its start as 1 September 2026 and estimates primary completion in July 2027. A second Phase 3, SUPREME-02, was not yet recruiting in October 2026.

Is CBL-514 being studied for other conditions?+

Yes. Small studies have tested it for cellulite and for Dercum disease, a rare condition with painful fatty lumps called lipomas. The FDA gave it Fast Track status for Dercum disease, which allows more frequent contact with the FDA during development. Caliway also says it has FDA and European orphan drug designations for Dercum disease. None of these is an approval.

Sources: Caliway website, read 15 November 2026; Caliway news release, 25 August 2026; Caliway news release on the animal study, 11 June 2026; Kybella label via openFDA; Wegovy label via openFDA; Phase 2 paper, 2025; Phase 2b paper, Aesthetic Surgery Journal, 2026; Phase 2a paper, Goodman and colleagues, 2022; ClinicalTrials.gov NCT07140939 (SUPREME-01); ClinicalTrials.gov NCT07733947; Dercum disease Phase 2a paper; Taiwan News report of a Caliway release, November 2024

What did we learn about CBL-514?

CBL-514 is an experimental small molecule designed to make fat cells in one spot shut themselves down. Three trials found less abdominal fat in the treated area, with small analysis groups and short follow-up. The survival enzyme story comes from company work that is not fully published, and the Zepbound idea comes from one animal study in a news release. As of 15 November 2026 it has no approval in any country.

Molecule Mechanics makes short cartoons about how drugs act inside the body, and lists every source under each one. This page sums up what the CBL-514 papers, registry entries and company releases say as of 15 November 2026. The voice you hear is synthetic, made with ElevenLabs, and the drawings are made for the channel. Earlier pages in the series cover octreotide, Foundayo, another drug that is not a peptide, and, first of all, tirzepatide.

Another weight drug still in trials is retatrutide, which our retatrutide calculator covers. If a fact here looks wrong to you, the steps for telling us are in our corrections policy.

Browse every Molecule Mechanics upload on YouTube

Sources: Molecule Mechanics channel

For learning only, and not medical advice. We built this page from trial papers, trial registries, FDA labels and records, and company releases about CBL-514, each named where it is used. CBL-514 is not approved, and any question about fat reduction treatment is for a licensed clinician.

Sources

  1. 1.Goodman GJ and colleagues, Phase 2a study of CBL-514 for abdominal fat, open-label, single site in Australia, February to November 2020 (NCT04698642), PMC9384315, full text read via Europe PMC: Caliway affiliation; cell results (fat breakdown and fat cell apoptosis) and animal results; the DYRK1b, caspase 3 and Bax/Bcl-2 statements cited to unpublished confidential company reports; deoxycholic acid described as relatively nonselective; 43 of 47 planned recruited because of COVID-19; per-protocol mean fat volume change of 24.96% at the first follow-up by ultrasound; every participant had at least one side effect; 8 of 43 withdrew because of side effects.
  2. 2.Phase 2 study of CBL-514 for abdominal fat (stage 2, US and Australia, 2022 to 2023, NCT04897412), PMC12080885, full text read via Europe PMC: small molecule from Caliway; nonclinical results cited to unpublished company reports; 76 randomized 2 to 1; 69.6% (16 of 23) against 0 of 16 lost at least 150 mL of fat at 8 weeks; more than 200 mL more fat lost than placebo at 4 weeks; 49.3% did not complete; mostly mild to moderate site reactions; one serious event judged unrelated; one case of hyperlipidemia judged probably related.
  3. 3.Phase 2b study of CBL-514 (CBL-0204, NCT05736107), Aesthetic Surgery Journal 2026, PMID 42159040, abstract read via NCBI E-utilities: 108 adults randomized 1 to 1; 76.7% (23 of 30) against 18.9% (7 of 37) improved by at least one grade on the clinician abdominal fat scale at the 12 week follow-up; MRI mean change of about 153 mL, or 20.3%; patient-rated results 23 of 30 against 7 of 36; mainly mild, short-lived site reactions. The registry lists 107 enrolled.
  4. 4.Review of injectable fat reduction, PMID 42488923, abstract read via NCBI E-utilities: deoxycholic acid is a bile acid found naturally in the body that helps break up fat in the gut; CBL-514 received Fast Track from the FDA.
  5. 5.Systematic review of fat-reducing injectables, published online November 2025, PMID 41296813: deoxycholic acid remains the only agent approved in the US for fat under the chin; more trials are needed on long-term results of injectables used elsewhere on the body.
  6. 6.KYBELLA (deoxycholic acid) label via openFDA, effective 11 September 2026: 12.1 says it physically destroys the cell membrane, causing lysis; approved only for fat under the chin in adults; warnings and common side effects.
  7. 7.Drugs@FDA, NDA 206333 (Kybella, AbbVie): original approval 29 April 2015.
  8. 8.WEGOVY (semaglutide) label via openFDA: works on the GLP-1 receptor, a regulator of appetite and food intake found in brain areas tied to appetite; its indication covers cutting excess body weight and holding that loss over time, alongside diet and physical activity.
  9. 9.FDA press announcement dated 8 November 2023: the agency cleared Zepbound (tirzepatide) for chronic weight management, for adults with obesity, and for overweight adults who have one or more health problems tied to weight.
  10. 10.Caliway news release, 25 August 2026 (via Placera): CBL-514 is a first-in-class small molecule designed to selectively induce fat cell apoptosis; FDA cleared the IND for the Phase 2 trial CBL-0201WR with Zepbound; SUPREME-01 began enrollment; founded 2012, Taiwan Stock Exchange code 6919. Company source.
  11. 11.Caliway news release, 11 June 2026 (via PR Newswire Asia), animal study OI25 presented at ADA 2026: weight regain after stopping of 46.1% with tirzepatide alone against 17.1% with CBL-514 added. Company source; species not named; not peer reviewed.
  12. 12.Caliway news release, 22 September 2026 (via ariva.de), Phase 2 CBL-0202DD in Dercum disease: mean pain score fell 3.1 points against 1.9 on placebo at week 20. Company-reported; not peer reviewed.
  13. 13.Taiwan News, report of a Caliway release, 13 November 2024: FDA Orphan Drug and Fast Track designations and an EMA orphan designation for Dercum disease. Company claim; agency registers not opened.
  14. 14.Caliway Biopharmaceuticals website, read 15 November 2026: CBL-514 is investigational, has not received marketing approval in any country or jurisdiction, and is not sold in any market. An openFDA Drugs@FDA search for sponsor Caliway on 15 November 2026 returned no application.
  15. 15.Phase 2a study of CBL-514 in Dercum disease, 12 adults in the US, open-label, October 2022 to April 2023 (NCT05387733), PMC12854054: median lipoma volume fell about 45% to 59% across groups and visits; no serious or fatal side effects; 4 severe; 2 stopped.
  16. 16.ClinicalTrials.gov, NCT04699669: Phase 1 safety study in 40 healthy volunteers in Australia, November 2018 to August 2019; randomized and double-blind except the last open-label groups.
  17. 17.ClinicalTrials.gov, NCT06005441: Phase 2b factorial study of CBL-514 against CBL-A1, CBL-A2 and placebo, 173 enrolled, completed 18 October 2024, no results posted.
  18. 18.ClinicalTrials.gov, NCT05836779 and NCT05632926: open-label Phase 2a cellulite studies of 23 and 12 participants, both completed.
  19. 19.ClinicalTrials.gov, NCT07140939 (SUPREME-01): Phase 3, randomized, placebo-controlled, triple masking in the registry field, about 320 planned in the US and Canada, actual start 1 September 2026, recruiting at the 19 October 2026 update, primary completion estimated July 2027; main goal a 2-grade gain on both a patient and a clinician abdominal fat scale.
  20. 20.ClinicalTrials.gov, NCT07526974 (SUPREME-02): second placebo-controlled Phase 3, about 320 planned in the US, Canada and Australia, not yet recruiting at the 20 October 2026 update.
  21. 21.ClinicalTrials.gov, NCT07733947: Phase 3b long-term follow-up and open-label extension for people who finish SUPREME-01 or SUPREME-02, about 300 planned, not yet recruiting, estimated start December 2026.